BioLineRx (BLRX) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 7:00 AM EDT- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance -
- Progressing critical Motixafortide pre-launch activities while maintaining full optionality on commercialization strategies -
- Cash and cash equivalents at March 31, 2022 of $50.6 million, sufficient to fund operations, as currently planned, into first half of 2024 -
- Management to hold conference call today, May 11, at 10:00 am EDT -
TEL AVIV,... More
